title: Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
abstract: BACKGROUND
  Rebound acid hypersecretion develops after the use of acid inhibitors.
  
  
  OBJECTIVE
  To estimate the duration of hypersecretion and to elucidate the role of the enterochromaffin-like (ECL) cell in rebound acid hypersecretion.
  
  
  METHODS
  Patients waiting for anti-reflux surgery who had used a proton pump inhibitor daily > 1 year were included. All patients discontinued taking acid inhibiting drugs after the operation. Basal and pentagastrin stimulated acid output was measured at 4, 8, 16 and 26 weeks postoperatively. Oxyntic mucosal biopsies were collected before and 26 weeks after the operation for counting of histidine decarboxylase (HDC) immunoreactive cells. Serum chromogranin A (CgA) and gastrin were measured before and at 4, 8, 16 and 26 weeks after the operation.
  
  
  RESULTS
  Pentagastrin stimulated acid secretion was higher at 4 and 8 weeks than at 26 weeks after the operation. Gastrin and CgA were significantly reduced at 4 and 8 weeks, respectively. The number of HDC immunoreactive cells was reduced by 60% at 26 weeks postoperative.
  
  
  CONCLUSIONS
  Rebound acid hypersecretion lasts more than 8 weeks, but less than 26 weeks after long-term proton pump inhibition.
  
  
  CONCLUSIONS
  The findings indicate that not only the parietal cell mass, but also ECL cell mass and activity are involved in the mechanism of acid hypersecretion.
authors.affiliation: Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. reidar.fossmark@medisin.ntnu.no
authors.forename: R
authors.initials: R
authors.lastname: Fossmark
authors.forename: G
authors.initials: G
authors.lastname: Johnsen
authors.forename: E
authors.initials: E
authors.lastname: Johanessen
authors.forename: H L
authors.initials: HL
authors.lastname: Waldum
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000863:Antacids / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D019861:Enterochromaffin-like Cells / Q000378:metabolism*; D004941:Esophagitis / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D064747:Lansoprazole; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D010418:Pentagastrin / Q000494:pharmacology; D054328:Proton Pump Inhibitors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D010418:Pentagastrin; D009853:Omeprazole